National LTC Pharmacy Advocacy Group Asks CMS to Release “Summary Data” on PBM Medicare Spread Pricing Activity
SCPC Thanks CMS for Curtailing PBM Medicaid Spread Pricing; Time for Similar Medicare Transparency…Read More.
‘An Arm And A Leg’: Why Are Drug Prices So Random? Meet Mr. PBM
Kaiser Health News
Surely, an old-time, generic drug can’t cost $720 — for a three-month supply…Read More.
As CMS Mitigates Medicaid ‘Spread Pricing’ Abuse, Time to Address Medicare Abuses
Under the leadership of Centers for Medicare and Medicaid Services Administrator Seema Verma, the Trump administration recently released key guidance mitigating pharmacy benefit managers’ abusive “spread pricing” practices in state Medicaid-managed care programs…Read More.
Drug middlemen name own prices, methodology goes unchallenged
The Columbus Dispatch
Ohio Medicaid officials and their managed-care contractors say they’re bringing new transparency to an opaque drug-delivery system that in 2017 saw more than a quarter-billion-dollar markup to taxpayers…Read More.
Two more big states take aim at PBM pricing practices, which one lawmaker calls ‘the wild west’
The controversial role that pharmacy benefit managers play in prescription drug pricing is under fresh attack in a pair of new reports issued by two of the largest state…Read More.
Consumers agree: Greater transparency among pharmacy benefit managers is needed
Recently, the Trump administration finalized a rule to require drug companies to disclose the list prices of their drugs in direct-to-consumer advertisements…Read More.
Parts Of HELP Bill Regulating PBMs Were Inspired By Montana Strategy
Inside Health Policy
Senate health committee chair Lamar Alexander (R-TN) and ranking Democrat Patty Murray (WA) included measures regulating pharmacy benefit managers in their draft bill on lowering health care costs that were inspired by a state official’s work in Montana…Read More.
States pursue aggressive drug pricing remedies; PBM, big pharma in crosshairs
States are taking aggressive actions to rein in high prescription treatment costs from pharmaceutical firms Opens a New Window. and curb potentially illicit behavior Opens a New Window. from middlemen price negotiators…Read More.
PBMs, under fire from the Trump administration, spend a record sum on lobbying
Lobbying disclosures filed on Monday revealed a flurry of pharmaceutical industry activity, including the largest-ever expenditure for the trade group representing pharmacy benefit managers….Read More.